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Pulmonary alveolar microlithiasis (PAM) is a rare disease characterized by the presence of small calculi in the alveolar space.
The authors report a case of a 21-year-old man with a 2-year history of shortness of breath on exertion and dry cough. Physical
examination was altered only for crackles at auscultation. Pulmonary function revealed a mild restrictive ventilatory defect and
the chest radiograph demonstrated paracardiac conﬂuence of dense micronodular inﬁltrate. High-resolution CT scan revealed
diﬀuse ground glass attenuation and septal thickening, more pronounced in lower pulmonary regions, with calciﬁcations along
the interlobar septa and subpleural regions. A transbronchial lung biopsy conﬁrmed the diagnosis of PAM.
1.Introduction
Pulmonary alveolar microlithiasis (PAM) is an uncommon
chronicdiseasecharacterizedbymultiplemicroscopiccalculi
within the alveoli and a paucity of symptoms in contrast to
the imaging ﬁndings [1–7]. Symptoms start at most cases
in the third and fourth decades of life. It is mostly accepted
now that the disease has an autosomal recessive inheritance
[2, 5, 8]. Recently, a few reports have described the role of
mutation in the type IIb sodium-phosphate cotransporter
gene(SCL34A2gene)inthediseasepathogenesis[9,10].The
authors present a case of symptomatic PAM in a 21-year-
old man, emphasizing the role of high-resolution lung CT
(HRCT) in the diagnosis of this unusual disease.
2.CaseReport
A 21-year-old male presented with a 2-year history of
progressiveshortnessofbreathonexertionanddrycough.At
physical examination, auscultation of the lungs has revealed
random wheezes and coarse crackles. Cardiac auscultation
was normal, and no cyanosis or peripheral edema was
observed. There was no history of smoking or previous
known pulmonary disease. On routine blood examination,
blood counts and serum chemistries were found to be
normal. Arterial blood gas analysis and echocardiography
showed no important abnormalities.
Pulmonaryfunctiontests(PFT)showedamildrestrictive
ventilatory defect, with a reduced total lung capacity of
79% (5.94L), forced vital capacity of 80% (4.18L) and a
forced expiratory volume in one second of 83% (3.72L).
The sputum was negative for acid-alcohol resistant bacillus
and human immunodeﬁciency virus testing was negative as
well.Thechestplainﬁlmsrevealedadiﬀusesymmetricdense
bilateral micronodular pattern (Figure 1). Based on this
ﬁnding, HRCT scan was obtained, revealing diﬀuse ground
glass attenuation and septal thickening, more pronounced
in lower pulmonary regions, with calciﬁcations along the
interlobar septa and subpleural regions. Subpleural cysts
were also noticed (Figure 2). The patient underwent a2 Case Reports in Medicine
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Figure 1: Chest radiographs in anteroposterior (a) and lateral (b) incidences shows a diﬀuse symmetric lung lesion with conﬂuence of dense
micronodular inﬁltrate. Note the, predominance of the lesions in the paracardiac regions of the lungs.
(a) (b)
(c) (d)
Figure 2: (a-b) High-resolution CT scan reveals diﬀuse ground glass attenuation and septal thickening, more pronounced in lower
pulmonaryregions.Notealsosubpleuralcysts.(c-d)Mediastinalwindowscansshowscalciﬁcationsalongtheinterlobarseptaandsubpleural
regions.
ﬁberoptic bronchoscopy with bronchoalveolar lavage and
transbronchial lung biopsy. The lavage ﬂuid was negative for
tuberculosis or fungi. Microliths were not found. Histology
revealed round, concentrically laminated microliths in the
alveoli associated with slightly thickened interstitial septa,
consistent with the diagnosis of PAM.
3. Discussion
PAM is a rare disease that presents chronic evolution, poorly
deﬁned etiology and pathogenesis, and is basically charac-
terized by numerous small calculi (denominated calciferites,
calcospherites or microlites) within air spaces [1–7, 11, 12].Case Reports in Medicine 3
Patients may remain asymptomatic for many years and do
usually become symptomatic between the third and fourth
decades [3, 6, 12]. At clinical presentation patients usually
demonstrate a lung disorder with restrictive pattern [3,
5–7, 12], as seen in our case. Adult patients commonly
show progressive deterioration of the pulmonary function
and death usually occurs in mid-life because of respiratory
failure associated with cor pulmonale [7, 13, 14]. Mean
age at the time of diagnosis in the literature is 35 years
and apparently there is no important predominance of
gender [2, 4, 12], The disease presents a high incidence of
familial occurrence (approximately one-third of the cases)
suggesting an autosomal recessive inheritance pattern [2,
5, 8, 12]. Chest X-ray of the parents and brother of the
patient in our case showed no signs of PAM. Recently, a
few reports have described the role of mutation in the type
IIb sodium-phosphate cotransporter gene (SCL34A2 gene),
whichisinvolvedinphosphatehomeostasisinseveralorgans,
including the lung [9, 10]. SCLC34A2 expression is observed
in type II alveolar cells. These cells use phospholipids to
produce surfactant and are also responsible for recycling and
degrading the outdated surfactant. It is believed that the
dysfunction in SCLC34A2 may reduce the clearance of the
phosphate released in this process, leading to the formation
of microliths. For this reason, it is now accepted that this
mutationisresponsibleforthepathologicchangesseeninthe
pulmonary parenchyma in PAM [10]. Disodium etidronate,
which inhibits microcrystal growth of hydroxyapatite and
thus inhibits ectopic calciﬁcation, has been used to treat
PAM. Although some reports show little or no beneﬁt with
the use of disodium etidronate [11, 12, 14, 15], a recent
study, regarding the long-term results of the treatment in
two cases, demonstrated an improvement at the patients
PFT and radiological changes [16]. Besides that, some
authors demonstrated the usage of measuring the serum
concentration of surfactant protein-A (SP-A) and surfactant
protein-D (SP-D) in patients with PAM. Alveolar type II
cells and Clara cells produce these two proteins in the lungs.
The diﬀuse parenchyma ﬁbrosis, consequent to PAM, causes
an increase in permeability, leading to an increase in the
levels of these two proteins in the blood. Therefore, SP-A
and SP-D measurement may be an alternative to monitor
the progression and activity of the disease. [17]. These
exams were not performed in our patient. Nevertheless,
no eﬀective treatment for end stage PAM currently exists,
with the exception of lung transplantation. Until then, seven
successful cases have been reported, with no recurrence of
the disease. Transplantation should be considered in cases
where either severe respiratory failure or right heart failure
are present. Patients who undergone lung transplantation
have showed an increase in right ventricular ejection fraction
and regression of right ventricular hypertrophy [14].
In the radiological diagnosis of PAM, chest radiographs
usually reveal diﬀuse, bilateral areas of micronodular cal-
ciﬁcations (“sand storm”) that predominate in the middle
and lower lung areas [2–7]. The heart borders and the
diaphragm are usually obliterated. Other typical ﬁnding
includes a black pleural line, demonstrated as an area of
increasedtranslucencebetweenthelungparenchymaandthe
ribs [2, 4, 5, 7]. The chest radiographs of our patient showed
ad i ﬀuse symmetric lung lesion with dense micronodular
aspect, corroborating the pattern described in the literature.
The HRCT ﬁndings in patients with alveolar microlithi-
asis vary considerably [2–7]. Ground-glass opacities are
the most common ﬁnding described in literature [2, 4, 5,
7]. This pattern occurs probably due to small calculi in
the air space. Subpleural linear calciﬁcation, conﬂuent and
diﬀuse calciﬁed nodules and dense consolidations are also a
common ﬁnding. Calciﬁcations along the bronchovascular
bundles and at the central region of the bronchovascular
tree can also be seen [2–7]. The CT scan conﬁrms a
predominance of symmetric calciﬁcations along the heart
borders and in the lower posterior portions of the lung [2–
4,7].Smallthin-walledsubpleuralcystsaredescribedaswell,
and they are responsible for the “black pleura” sign seen
in the chest X-rays [2, 4, 5, 11]. Recently, it was described
the unique characteristics of the mosaic pattern seen in
alveolar microlithiasis, in which the interlobular septa are of
calcium density due to the deposition of calcipheriths within
the peripheral lobular parenchyma, adjacent to the septa.
Some authors consider this pattern very speciﬁc and even
pathognomonic of PAM on the HRCT scan, since this aspect
has not been described in any other disease [2, 7]. Clinicians
should have in mind that some ﬁndings seen in PAM, such
as nodular calciﬁcations, can be found in other diseases
like tuberculosis, metastatic osteosarcoma, amyloidosis and
silicoproteinosis. Besides that, dense consolidations can also
be found in metastatic pulmonary calciﬁcation, talcosis and
amiodarone lung toxicity. In this way, associated CT ﬁndings
and clinical features should always be correlated, since these
diseases have diﬀerent kinds of presentation and evolution
[18].
In conclusion, PAM is a rare disease that can aﬀect
young patients, with chronic and deteriorating evolution.
Cliniciansshouldbeawareofitexistenceandtheradiological
features associated. The micronodular pattern seen in chest
radiography can sometimes be misdiagnosed as miliary
tuberculosis or other diseases that present with this pattern.
In this way, HRCT should always be performed since it
can reveal characteristic patterns of alveolar microlithiasis,
reserving lung biopsy for atypical and inconclusive cases.
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